Eosinophilic Gastroenteritis Medical Services in China

Eosinophilic gastroenteritis (EGE) is a rare, chronic, immune-mediated gastrointestinal disorder characterized by eosinophilic infiltration of the gastrointestinal (GI) tract wall—spanning from the esophagus to the colon—without evidence of parasitic infection, malignancy, or systemic eosinophilic disease. It predominantly affects the stomach and small intestine but may involve any GI segment. Histologically, diagnosis requires ≥20 eosinophils per high-power field (HPF) in gastric or intestinal biopsies, alongside clinical symptoms and exclusion of secondary causes. Pathogenesis remains incompletely understood but involves dysregulated T-helper 2 (Th2) immune responses, aberrant cytokine signaling (notably IL-5, IL-4, and eotaxin), and antigen-driven eosinophil recruitment and activation. Genetic predisposition (e.g., polymorphisms in IL-5Rα and FCER1A), environmental triggers (food allergens such as milk, egg, wheat, soy, nuts), and impaired mucosal barrier function likely contribute synergistically. Epidemiologically, EGE is exceedingly rare, with an estimated incidence of 0.007–0.013 per 100,000 person-years and prevalence under 10 per million. It affects all ages but peaks in adults aged 30–50 years; pediatric cases are increasingly recognized. There is no strong gender predilection, though some studies report slight male predominance. Risk factors include personal or familial atopy (asthma, allergic rhinitis, eczema), food allergy history, elevated serum IgE, and peripheral eosinophilia (>500/μL). Clinical presentation varies by layer involvement: mucosal disease causes abdominal pain, nausea, vomiting, diarrhea, iron-deficiency anemia, hypoalbuminemia, and protein-losing enteropathy; muscular involvement leads to obstructive symptoms (e.g., gastric outlet obstruction, intussusception); serosal disease may present with ascites and peripheral eosinophilia. Diagnosis relies on endoscopic biopsy with histopathology, imaging (CT/MRI showing bowel wall thickening, fluid accumulation), and comprehensive workup to rule out hypereosinophilic syndrome, parasitic infestation (e.g., Strongyloides), vasculitis, lymphoma, and celiac disease. Untreated or poorly controlled EGE significantly impairs quality of life—patients frequently experience chronic fatigue, dietary restrictions, social isolation due to unpredictable GI flares, anxiety around eating, work absenteeism, and reduced physical functioning. Children may suffer growth failure and nutritional deficits. Long-term complications include strictures, malnutrition, spontaneous perforation (rare), and corticosteroid-related morbidity. Early multidisciplinary management—including allergology, nutrition support, and gastroenterology—is essential to mitigate disease burden and preserve GI integrity.

Eosinophilic gastroenteritis (EGE) is a rare, chronic, immune-mediated disorder characterized by eosinophilic infiltration of the gastrointestinal (GI) tract in the absence of parasitic infection, malignancy, or systemic eosinophilic disease. Diagnosis requires histopathological confirmation of ≥20 eosinophils per high-power field (HPF) in gastric or intestinal biopsies, coupled with clinical symptoms such as abdominal pain, diarrhea, nausea, vomiting, early satiety, weight loss, and occasionally protein-losing enteropathy or obstructive features. Management is multidisciplinary and tailored to disease extent (mucosal, muscular, or serosal), symptom severity, and endoscopic/histologic findings. Treatment strategies fall into three broad categories: conservative (dietary and lifestyle), pharmacologic, and surgical—each employed sequentially or in combination based on response and complications.

Conservative treatment serves as the cornerstone for mild-to-moderate mucosal-predominant EGE and is especially critical in pediatric and young adult patients. Elimination diets—most rigorously the six-food elimination diet (SFED: excluding cow’s milk, soy, wheat, egg, peanut/tree nuts, and seafood)—are first-line non-pharmacologic interventions. Evidence supports SFED-induced histologic remission in up to 75% of responsive patients within 6–8 weeks. Elemental diets (amino acid-based formulas) are reserved for refractory cases or severe malnutrition, particularly in children, achieving remission rates exceeding 85% but with significant adherence challenges. Nutritional counseling by registered dietitians specializing in eosinophilic GI disorders is mandatory to prevent micronutrient deficiencies (e.g., vitamin D, calcium, iron, B12) and ensure caloric adequacy. Patients are advised to maintain food/symptom diaries and undergo periodic nutritional assessment. Lifestyle modifications include stress reduction (given neuroimmune interactions), avoidance of NSAIDs (which may exacerbate mucosal inflammation), and smoking cessation (smoking correlates with increased eosinophil activation).

Pharmacotherapy is initiated when conservative measures fail, symptoms are moderate-to-severe, or extraintestinal manifestations (e.g., peripheral eosinophilia >1,500/μL, ascites) are present. Corticosteroids remain the most effective induction agents: oral budesonide (9 mg/day for adults, weight-adjusted in children) offers targeted mucosal anti-inflammatory action with markedly reduced systemic exposure compared to prednisone. For diffuse or deep-layer involvement, short-course systemic corticosteroids (prednisone 0.5–1 mg/kg/day for 2–4 weeks, followed by taper over 8–12 weeks) are preferred. Maintenance therapy may involve low-dose budesonide or leukotriene receptor antagonists (e.g., montelukast 10 mg daily), though evidence for long-term monotherapy is limited. Biologics represent a paradigm shift for steroid-dependent or refractory EGE. Mepolizumab, benralizumab, and dupilumab have demonstrated efficacy in case series and small trials by targeting IL-5 or IL-4/IL-13 pathways—key drivers of eosinophilopoiesis and tissue recruitment. Dupilumab (300 mg SC weekly after loading dose) shows particular promise in patients with concurrent atopic comorbidities. Other immunomodulators—including azathioprine (2–2.5 mg/kg/day) and methotrexate (15–25 mg/week)—may be considered for steroid-sparing maintenance, though data are extrapolated from eosinophilic esophagitis and require careful monitoring for hepatotoxicity and myelosuppression.

Surgical intervention is rarely indicated and reserved exclusively for life-threatening complications. These include acute intestinal obstruction due to muscularis propria hypertrophy, perforation secondary to ulceration or necrosis, massive hemorrhage unresponsive to endoscopic control, or intractable protein-losing enteropathy with recurrent ascites refractory to medical therapy. Procedures range from segmental resection (e.g., ileal or colonic resection) to partial gastrectomy in severe gastric involvement. Laparoscopic approaches are favored where feasible to minimize postoperative morbidity. Surgery does not address the underlying immune dysregulation; thus, perioperative corticosteroid coverage and prompt resumption of medical therapy are essential to prevent recurrence in adjacent or residual mucosa.

China offers distinct advantages in EGE management, rooted in integrated healthcare infrastructure and rapidly evolving expertise. Major tertiary hospitals—such as Peking Union Medical College Hospital, West China Hospital, and Shanghai Renji Hospital—host dedicated eosinophilic GI disease centers with multidisciplinary teams (gastroenterologists, allergists, pathologists, dietitians, and clinical immunologists). These centers utilize standardized histopathologic protocols, including eosinophil quantification via digital pathology platforms and rigorous exclusion criteria for parasitic infections (e.g., stool PCR for Strongyloides, serum IgE against Ascaris/Taenia). Access to biosimilars and domestically manufactured biologics (e.g., dupilumab biosimilars approved under NMPA guidelines) significantly reduces treatment cost versus Western markets. Furthermore, China’s national real-world evidence initiatives (e.g., the China Eosinophilic GI Disease Registry) facilitate rapid data aggregation on treatment responses, enabling personalized algorithms. Traditional Chinese Medicine (TCM) adjuncts—such as modified Si Jun Zi Tang or Shen Ling Bai Zhu San—are increasingly studied in randomized controlled trials for symptom modulation and steroid-sparing effects, though they are never used as monotherapy and always under integrated supervision.

Recovery and long-term management emphasize vigilant monitoring and patient empowerment. Patients should undergo repeat upper/lower endoscopy with systematic biopsies every 3–6 months during active treatment and annually in sustained remission to assess histologic response—clinical improvement alone is insufficient. Laboratory surveillance includes CBC with differential, albumin, IgE, and liver/kidney function tests. Vaccination status (especially pneumococcal and influenza) must be optimized prior to immunosuppression. Psychological support is integral: chronic GI symptoms correlate strongly with anxiety and depression, and cognitive behavioral therapy has shown benefit in symptom perception and coping. Patients are counseled that EGE is typically relapsing-remitting; however, with structured care, >80% achieve durable remission (>2 years) without disability. Pregnancy planning warrants preconception optimization, as uncontrolled disease increases risks of fetal growth restriction. Finally, patients should carry emergency steroid cards and receive clear written action plans for symptom flares—including when to seek urgent evaluation for signs of obstruction (bilious vomiting, absolute constipation) or ascites progression. Through coordinated, evidence-informed, and culturally attuned care, EGE can be effectively managed as a chronic but controllable condition.